varenicline sold brand names chantix champix among others medication used smoking treatment dry eye nicotinic receptor partial cholinergic activated receptor releases dopamine nucleus accumbens brains reward center thereby reducing cravings withdrawal symptoms associated smoking common side effects varenicline include nausea insomnia abnormal dreams headache nasopharyngitis inflammation nose despite potential adverse effects varenicline proven efficacy helping individuals quit smoking estimated approximately one eleven smokers use varenicline successfully remain abstinent tobacco six world health organizations list essential medication available generic united states varenicline prescribed million times ranking commonly prescribed varenicline indicated use aid smoking cessation treatment signs symptoms dry eye varenicline used help people stop smoking tobacco smoking cessation metaanalysis found people treated varenicline remain abstinent smoking one metaanalysis varenicline found effective bupropion odds ratio nicotine replacement therapies nrt odds ratio cochrane overview network metaanalysis concluded varenicline effective medication tobacco cessation smokers nearly three times likely quit tobacco use varenicline placebo treatment varenicline efficacious bupropion nrt effective combination nrt cessation tobacco mild nausea common side effect seen approximately people taking varenicline though rarely results discontinuation less common side effects include headache difficulty sleeping vivid dreams rare side effects reported people taking varenicline compared placebo include change taste vomiting abdominal pain flatulence constipation estimated every five subjects taking varenicline maintenance doses one event nausea every treated subjects event constipation flatulence gastrointestinal sideeffects lead discontinuation drug people using incidence nausea dosedependent incidence nausea higher people taking larger dose versus placebo compared people taking smaller dose versus placebo us food drug administration fda announced received postmarketing reports thoughts suicide occasional suicidal behavior erratic behavior drowsiness among people using varenicline smoking cessation fda required varenicline carry boxed warning medication stopped symptoms systematic review literature research find evidence increased suicide analyses reached conclusion found increased risk neuropsychiatric side effects evidence increased risks cardiovascular events depression selfharm varenicline versus nicotine replacement therapy found one postmarketing surveillance fda removed black box people still advised stop medication notice side effects mood behavior june us fda issued safety announcement varenicline may associated small increased risk certain cardiovascular adverse events people cardiovascular prior review found increased risk cardiovascular events compared expert commentary journal raised doubts methodology concerns echoed european medicines agency subsequent specific concern low number events seen types events counted higher dropout rate people receiving placebo lack information timing events exclusion studies noone event contrast multiple recent systematic reviews metaanalyses found increase overall serious adverse cardiovascular events including individuals risk developing cardiovascular disease associated varenicline varenicline displays full agonism nicotinic acetylcholine receptors partial agonist vareniclines partial agonism receptors rather nicotines full agonism produces less effect dopamine release nicotines competitive binding reduces ability nicotine bind stimulate mesolimbic dopamine method action buprenorphine treatment opioid active compound excreted kidneys small proportion glucuronidated oxidised nformylated conjugated use cytisus plants smoking substitutes world war led use cessation aid eastern europe extraction cytisine analogs led varenicline varenicline received priority review us fda february shortening usual tenmonth review period six months demonstrated effectiveness clinical trials perceived lack safety agencys approval drug came may september approved sale european september pfizer announced recall lots antismoking treatment chantix varenicline due high levels cancercausing agents called nitrosamines followed july announcement fda alerting patients health care professionals pfizers voluntary recall nine lots smoking cessation drug recalls pfizer july june pfizer paused distribution chantix distribution halt abundance caution pending testing company said according pfizer inc form annual report highrevenue products company included chantixchampix varenicline treat nicotine addiction recorded direct product revenues billion million million lower revenue due part basic product patent expiration chantix us november europe september aforementioned pfizer voluntary recall across multiple markets global pause shipments october us fda approved oyster point pharma market tyrvaya new route varenicline administration nasal spray treatment dry eye httpsenwikipediaorgwikivarenicline